The health care sector has staged a strong multiyear recovery, and Johnson & Johnson (NYSE:JNJ)
has more than just gone along for the ride. Although the company has
had to deal with major recalls in the consumer business and unimpressive
growth in the device business, the pharmaceutical business has emerged
as a real star with six blockbusters introduced in the last five years.
Nothing
lasts forever, though, and 2015 is shaping up as a more challenging
year. Headwinds in the pharmaceutical business appear to be coinciding
with forex-related pressure and the device business is unlikely to
accelerate enough to make up the difference. None of this makes Johnson
& Johnson a bad company, though, and investors may want to keep an
eye on these shares for the opportunity to pick up a potential long-term
holding at an attractive price.
Read more here:
Johnson & Johnson Finding Growth A Little Harder Now
No comments:
Post a Comment